Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments
Under the terms of the agreement, Pieris will provide Glycostem with Anticalin constructs against immune targets to be combined with Glycostem’s oNKord® technology to study the combined potential of the technologies in the treatment of solid tumors.
Read moreThe Netherlands is putting its mark on the map of innovative pharmacy
Innovation within the pharmaceutical sector. This topic was discussed more than ever in 2020-2021.
Read moreELF paper selected for print in a special issue of SLAS Discovery
European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
Read morePharmSupport and the HAN developed a post-graduate course
Pivot Park gaat intensief samenwerken met de Hogeschool van Arnhem en Nijmegen (HAN).
Read moreRadboud Summer School at Pivot Park
Pivot Park gaat intensief samenwerken met de Hogeschool van Arnhem en Nijmegen (HAN).
Read moreTRIAS nieuwe sponsor LifetecZONe
Met ingang van dit jaar is subsidieadviesbureau TRIAS de nieuwe sponsor van LifetecZONe.
Read more2020 highlights Pivot Park Community
Read here a short summary of the 2020 highlights of our Community members
Read moreAdaptVac partners with BioConnection to manufacture their COVID-19 vaccine
BioConnection announces that it is collaborating with AdaptVac for the Drug Product manufacture of their COVID-19 vaccine.
Read more